|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Apexigen
|
|
gptkbp:ceo
|
gptkb:Vivek_Ramaswamy
|
|
gptkbp:clinical_trial
|
gptkb:Oncology
gptkb:neurodegenerative_diseases
gptkb:multiple_sclerosis
Phase 1
rare diseases
Phase 2
Phase 3
preclinical
|
|
gptkbp:collaboration
|
gptkb:Duke_University
gptkb:Harvard_University
gptkb:Stanford_University
gptkb:University_of_California,_San_Francisco
gptkb:Yale_University
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._David_H._H._Hwang
|
|
gptkbp:focus
|
drug development
|
|
gptkbp:founded
|
gptkb:2014
|
|
gptkbp:founder
|
gptkb:Vivek_Ramaswamy
|
|
gptkbp:funding
|
gptkb:Series_A
gptkb:Series_B
Series C
IPO
|
|
gptkbp:head_of_state
|
Dr. John H. H. Hwang
Dr. Michael A. H. Hwang
|
|
gptkbp:headcount
|
over 300 employees
|
|
gptkbp:headquarters
|
gptkb:New_York_City
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Roivant Sciences
|
|
gptkbp:investment
|
$1.1 billion
|
|
gptkbp:market_cap
|
$7 billion (2021)
|
|
gptkbp:notable_products
|
RVT-104
RVT-1401
RVT-1501
RVT-601
RVT-901
|
|
gptkbp:partnership
|
gptkb:Takeda_Pharmaceutical_Company
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
|
|
gptkbp:research_focus
|
neurology
oncology
rare diseases
immunology
metabolic diseases
|
|
gptkbp:revenue
|
$100 million (2021)
|
|
gptkbp:stock_symbol
|
ROIV
|
|
gptkbp:subsidiary
|
Axovant Gene Therapies
Urovant Sciences
Myovant Sciences
Enzyvant Therapeutics
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.roivant.com
|
|
gptkbp:bfsParent
|
gptkb:Vivek_Ramaswamy
|
|
gptkbp:bfsLayer
|
6
|